VOR catalyst calendar

Vor Biopharma Inc.

Upcoming catalysts
2
Cash runway
36.6 months
Cash & investments
$466M
Phase 3 programs
3

Vor Biopharma Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) on May 15, 2027. There are 2 upcoming events on record.

Cash runway is approximately 36.6 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 5 concluded trials, 0% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
May 15, 2027 A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) Trial Milestone Phase 3
December 15, 2028 Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease Trial Milestone Phase 3

Track VOR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open VOR in the tracker

Recent history

DateEventTypePhase
July 7, 2026 8-K filed: Leadership change Corporate —
June 8, 2026 8-K filed: Reg FD disclosure Filing —
March 27, 2026 8-K filed: Material agreement, Reg FD disclosure Corporate —
January 12, 2026 Quarterly results filed (8-K) Earnings —
January 2, 2026 8-K filed: Leadership change Corporate —
December 18, 2025 8-K filed: Material agreement, Leadership change, Reg FD disclosure Corporate —
December 9, 2025 8-K filed: Leadership change Corporate —
November 12, 2025 8-K filed: Other event Filing —
November 3, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
October 28, 2025 8-K filed: Reg FD disclosure Filing —
September 17, 2025 8-K filed: Other event Filing —
September 2, 2025 8-K filed: Reg FD disclosure Filing —
August 27, 2025 8-K filed: Leadership change, Other event Corporate —
August 27, 2025 8-K filed: Leadership change Corporate —
July 22, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
July 10, 2025 8-K filed: Leadership change, Reg FD disclosure Corporate —
June 26, 2025 8-K filed: Material agreement, Leadership change, Reg FD disclosure Corporate —
May 28, 2025 Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS Trial Milestone Phase 1/Phase 2
May 28, 2025 Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant Trial Milestone Phase 1/Phase 2
May 20, 2025 8-K filed: Leadership change Corporate —
May 8, 2025 8-K filed: Leadership change, Other event Corporate —
April 25, 2025 8-K filed: Listing / standard notice Corporate —
January 6, 2025 A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1) Trial Milestone Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.